[1] PENG L, WANG D, SHEN L, et al.Development and Origin of Pharmacovigilance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(7): 410-413. [2] WHO. Importance of Pharmacovigilance(safety monitoring of medicinal products)[R]. 2002. [3] The European Parliament and the Council of the European Union.Medical device regulation(EU)2017/745[EB/OL].(2017-04-05)[2023-01-15]. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745. [4] NMPA.“14th Five Year Plan”National Drug Safety and Promotion of High Quality Development Plan([EB/OL]. (2021-12-30)[2023-08-01]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20211230192314164.html. [5] NMPA. Opinions of the State Drug Administration on Further Strengthening the Adverse Drug Reaction Monitoring and Evaluation System and Capacity Building[EB/OL].(2020-07-28) [2023-09-20]. https://www.gov.cn/zhengce/zhengceku/2020-07/30/content_5531258.htm. [6] SAMR.Administrative Measures for Monitoring and Re-evaluation of Adverse Events of Medical Devices[EB/OL].(2018-08-13) [2023-05-20]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_4b69cde387db4c4fa4465aad987157e0.html. [7] SHEN CY, SONG YN, ZHAO Y, et al.Thoughts on constructing vigilance system of Chinese medical device in the new era[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 697-701. [8] FDA. Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval; Guidance for Industry and Food and Drug Administration Staff[EB/OL]. (2018-02-05)[2023-05-20]. https://www.regulations.gov/docket/FDA-2014-D-0090. [9] FDA. Webinar - Final Guidances on Post-Approval Study Requirements and Postmarket Surveillance under Section 522 of the Federal Food, Drug,Cosmetic Act[EB/OL].(2022-12-15)[2023-05-20]. https://www.fda.gov/medical-devices/workshops-conferences-medical-devices/webinar-final-guidances-post-approval-study-requirements-and-postmarket-surveillance-under-section. [10] FDA. Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry and Food and Drug Administration Staff; Availability[EB/OL].[2022-10-07]. https://www.regulations.gov/document/FDA-2011-D-0514-0015. [11] GLIKLICH RE, DREYER NA, LEAVY MB.Registries for evaluating patient outcomes:a user’s guide[R]. Rockvile(MD): Agency for Healthcare Research and Quality(US), 2014. [12] ZHAO Y, LIU WB, ZHAO YF, et al.Applicability of patient registry research to regulation of medical devices[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(4): 423-427. [13] FDA. Food and Drug Administration Amendments Act[EB/OL].(2018-03-29) [2023-05-20]. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-amendments-act-fdaaa-2007. [14] FDA. FDA Sentinel Program[EB/OL].[2023-08-01].https://www.sentinelinitiative.org. [15] NMPA. Regulatory Information[EB/OL].[2023-08-01]. https://www.nmpa.gov.cn/xxgk/ggtg/index.html. [16] LI XH, ZHAI W, MA N, et al.Prospective study of bone plate event in Beijing[J]. China Medical Device Information(中国医疗器械信息), 2017, 23(17): 14-17, 37. [17] YU Y, ZHAI W, LIN W, et al.Current status and analysis of overseas and demestic medical device registry study[J]. China Medical Device Information(中国医疗器械信息), 2021, 27(1): 1-3, 167. [18] GU DC, ZHAO Y, ZHANG Y, et al.Establishment of Chinese cardiovascular surgery registry database[J]. Chinese Circulation Journal(中国循环杂志), 2017, 32(10): 1010-1014. [19] Jiangsu Adverse Drug Reaction Monitoring Center. Jiangsu Medical Device Monitoring Information System[EB/OL].[2023-05-20]. http://www.jsadr.org.cn/ylqxjc/. [20] Central People’s Government of the People’s Republic of China. General Office of the State Council issues Implementation Opinions on Comprehensively Strengthening Drug Regulatory Capacity Building[EB/OL].(2021-05-10)[2022-01-06].http://www.gov.cn/xinwen/2021-05/10/content_5605647.htm. [21] CALLAHAN A, FRIES JA, RÉ C, et al.Medical device surveillance with electronic health records[J]. NPJ Digit Med, 2019, 2: 94. [22] BANERJEE S, CAMPBELL B, RISING J, et al.Long-term active surveillance of implantable medical devices: an analysis of factors determining whether current registries are adequate to expose safety and efficacy problems[J]. BMJ Surg Interv Health Technol, 2019, 1(1): e000011. |